Table 1.
In vivo models and potential biomarkers for ATG4B inhibition in cancer
| Cancer Type | Therapeutic Modality | In Vivo Model | Biomarker |
|---|---|---|---|
| Breast cancer | siRNA ATG4B/Trastuzumab | MCF7 xenograft | HER2, ATG4B |
| Colorectal cancer | Tioconazole | HCT-116 Xenograft | none |
| Colorectal cancer | S130/Caloric restriction | HCT-116 Xenograft | none |
| Colorectal cancer | UAMC2526/oxaliplatin | HT-29 Xenograft | LC3 conversion |
| Glioblastoma | NSC185058/Chloroquine | M83 glioma xenograft | none |
| Lung adenocarcinoma | Doxicylcin-inducible ATG4B C74A | GEMM | K-Ras mutation |
| Osteosarcoma | NSC185058/starvation | SAOS Xenograft | none |
| Pancreatic ductal adenocarcinoma | Doxicyclin-inducible ATG4B C74A | GEMM | K-Ras mutation |
| Prostate cancer | ATG4B C74A/doxorubicin | PC-3 Xenograft | none |